TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37683518
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy plus standard care
Study: 37683686
Drug: upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 30 mg once daily
Study: 37683799
Drug: 3 M True
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 M True Definition Intraoral Scanner or 3 M Lava Chairside Oral Scanner
Study: 37684332
Drug: Nasal-spraying Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal-spraying Bacillus spores (LiveSpo Navax) containing 5 billion of Bacillus subtilis and B. clausii spores in 5 mL.
Study: 37684373
Drug: TRC105 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC105 monotherapy (10 mg/kg)
Study: 37684682
Drug: Link work
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Link work intervention (treatment as usual plus a link worker intervention) consisting of six sessions over 9 months.
Study: 37684682
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control).
Study: 37685975
Drug: Citrus and
Normalized name: Chloroxylenol 0.003 g in 1 mL TOPICAL SOAP [Clorox Citrus and Sage Dish]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus and pomegranate complex (CPC) 500 mg
Study: 37686032
Drug: Runcaciguat 1
Normalized name: Runcaciguat
DrugBank: Runcaciguat (DB16700)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Runcaciguat 1 mg/kg/bid
Study: 37686032
Drug: Runcaciguat 3
Normalized name: Runcaciguat
DrugBank: Runcaciguat (DB16700)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Runcaciguat 3 mg/kg/bid
Study: 37686032
Drug: Runcaciguat 10
Normalized name: Runcaciguat
DrugBank: Runcaciguat (DB16700)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Runcaciguat 10 mg/kg/bid
Study: 37689018
Drug: High-dose (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (60 Gy) IMRT with weekly cisplatin
Study: 37689323
Drug: Active transcranial
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transcranial direct current stimulation (a-tDCS) on left dorsolateral prefrontal cortex (l-DLPFC), n=34
Study: 37689323
Drug: Sham transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham transcranial direct current stimulation (s-tDCS) on l-DLPFC, n=17
Study: 37689749
Drug: High-dose carboplatin-thiotepa-cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carboplatin-thiotepa-cyclophosphamide
Study: 37689749
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (ddAC only or ddAC-capecitabine/decetaxel [CD] or ddAC-carboplatin/paclitaxel [CP])
Study: 37689749
Drug: High-dose alkylating
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alkylating chemotherapy
Study: 37689822
Drug: Pharmacogenetic testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic testing panel for 26 drugs
Study: 37689822
Drug: Pharmacogenetic testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic testing panel for aripiprazole and serotonin or serotonin-norepinephrine reuptake inhibitors
Study: 37690061
Drug: Lorundrostat 100
Normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorundrostat 100 mg once daily
Study: 37690061
Drug: Lorundrostat 50
Normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorundrostat 50 mg once daily
Study: 37690061
Drug: Lorundrostat 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorundrostat 12.5 mg once daily
Study: 37690061
Drug: Lorundrostat 25
Normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorundrostat 25 mg twice daily
Study: 37690061
Drug: Lorundrostat 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorundrostat 12.5 mg twice daily
Study: 37690061
Drug: Lorundrostat 100
Normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorundrostat 100 mg once daily (participants without suppressed PRA)
Study: 37690061
Drug: Lorundrostat 50
Normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorundrostat 50 mg once daily vs Placebo
Study: 37690061
Drug: Lorundrostat 100
Normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorundrostat 100 mg once daily vs Placebo
Study: 37690784
Drug: High-dose (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (40 mg/day)
Study: 37690784
Drug: Low-dose (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (20 mg/day)
Study: 37690874
Drug: CHIKV VLP
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHIKV VLP vaccine in seropositive recipients
Study: 37690874
Drug: CHIKV VLP
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHIKV VLP vaccine in seronegative recipients
Study: 37691092
Drug: App-based management
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based management system for chronic pain patients with SCS implants
Study: 37691092
Drug: Monthly online
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly online follow-ups
Study: 37691144
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with connective tissue graft (CTG) and individualized supportive peri-implant care (SPC) program
Study: 37691729
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) 50 mg
Study: 37691729
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) 100 mg
Study: 37691729
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) 100 mg (for nonresponders)
Study: 37691796
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (active control)
Study: 37691850
Drug: Menthol solution
Normalized name: Menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol solution 0.01%
Study: 37691850
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - noncaloric berry-flavored solution
Study: 37691885
Drug: Paclitaxel liposome,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel liposome, cisplatin and 5-fluorouracil (TPF)-based induction chemotherapy followed by de-escalated radiotherapy of 60 Gy with concurrent cisplatin
Study: 37691885
Drug: Paclitaxel liposome,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel liposome, cisplatin and 5-fluorouracil (TPF)-based induction chemotherapy followed by standard-dose radiotherapy of 70 Gy with concurrent cisplatin (for those with stable or progressive disease)
Study: 37692126
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg every 4 weeks for 52 weeks
Study: 37692969
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of nabiximols (up to 113.4 mg THC/105 mg CBD)
Study: 37693269
Drug: Retreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment with first-line anti-HCV drugs for 24 weeks with ribavirin
Study: 37693269
Drug: Overall retreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall retreatment with first-line anti-HCV drugs
Study: 37693433
Drug: Pre-treatment functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment functional connectivity of the seed with the cerebellum, insula, middle occipital gyrus, postcentral gyrus, and precuneus/superior parietal lobule.
Study: 37693433
Drug: Pre-treatment functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment functional connectivity with the putamen.
Study: 37693433
Drug: Pre- to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- to post-treatment changes in functional connectivity.
Study: 37693433
Drug: Pre-treatment functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment functional connectivity between regions involved in attentional salience, self-generated thoughts, and external attention.
Study: 37693586
Drug: Pre-treatment histidine
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-treatment histidine concentration
Study: 37693586
Drug: Pre-treatment concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment concentrations of glutamate
Study: 37693586
Drug: Pre-treatment concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment concentrations of phenylalanine
Study: 37693586
Drug: Pre-treatment concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment concentrations of tyrosine
Study: 37693586
Drug: Pre-treatment concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment concentrations of valine
Study: 37693768
Drug: Low-frequency rTMS
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency rTMS (30 min) followed by occupational therapy (30 min) for 10 consecutive workdays
Study: 37693768
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS (30 min) followed by occupational therapy (30 min) for 10 consecutive workdays
Study: 37694347
Drug: T-DXd 5.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DXd 5.4 mg/kg
Study: 37694347
Drug: T-DXd 6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DXd 6.4 mg/kg
Study: 37694449
Drug: Garetosmab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garetosmab (10 mg/kg, intravenous, every 4 weeks)
Study: 37694449
Drug: Placebo (intravenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous, every 4 weeks)
Study: 37696393
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept treatment
Study: 37696588
Drug: Bimekizumab (BKZ)
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Bimekizumab (BKZ) 160 mg every 4 weeks
Study: 37696588
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) 40 mg every 2 weeks
Study: 37696588
Drug: Bimekizumab (BKZ)
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Bimekizumab (BKZ) 160 mg every 4 weeks (after switch from PBO at Week 16)
Study: 38279364
Drug: Otilimab 90
Normalized name: Otilimab
DrugBank: Otilimab (DB06303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilimab 90 mg
Study: 37699654
Drug: Otilimab 150
Normalized name: Otilimab
DrugBank: Otilimab (DB06303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilimab 150 mg
Study: 37696629
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg melatonin administered rectally via an enema daily for 28 days
Study: 37696629
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered rectally via an enema daily for 28 days
Study: 37696935
Drug: lefitolimod (TLR9
Approvals — FDA: no, EMA: no, PMDA: no
Description: lefitolimod (TLR9 agonist)/placebo
Study: 37696935
Drug: placebo/broadly neutralizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo/broadly neutralizing anti-HIV-1 antibodies (bNAbs)
Study: 37697331
Drug: Secondary factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary factors (symptoms, activity level, activities of daily living, sport)
Study: 37697491
Drug: Oral rinse
Normalized name: Oral Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rinse activated matrix metalloproteinase-8 (aMMP-8) point-of-care test (POCT)
Study: 37697666
Drug: Ultrasound-guided hydrodilatation
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided hydrodilatation with hyaluronic acid (20 mL in total) + physical therapy
Study: 37697666
Drug: Ultrasound-guided hydrodilatation
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided hydrodilatation with hyaluronic acid + physical therapy
Study: 37697813
Drug: Heparin bridging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin bridging strategy used during edoxaban interruption (178 procedures)
Study: 37698478
Drug: High-dose Erythropoietin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Erythropoietin
Study: 37698662
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of triamcinolone acetonide (TA) (40 mg) and VISCOAT (sodium chondroitin sulfate 20 mg and sodium hyaluronate 15 mg)
Study: 37698662
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TA) (40 mg) in the posterior subtenon space
Study: 37698662
Drug: Suprachoroidal triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suprachoroidal triamcinolone (4 mg/100µl)
Study: 37698660
Drug: Modified Monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Monthly Regimen (mMR), total dose-5.5 g, with intake of oral GCs after completion of intravenous infusions.
Study: 37698660
Drug: Weekly Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly Regimen (WR), total dose-4.5 g.
Study: 37698660
Drug: Modified Monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Monthly Regimen (mMR)
Study: 37698660
Drug: Weekly Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly Regimen (WR)
Study: 37698745
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health exercise intervention (daily steps and resistance training data entered into an app)
Study: 37698836
Drug: 120-mg galcanezumab
Normalized name: galcanezumab-gnlm 120 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120-mg galcanezumab
Study: 37698836
Drug: 240-mg galcanezumab
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 240-mg galcanezumab
Study: 37699050
Drug: E-liquids with
Normalized name: Aquasol E Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-liquids with 20 mg/mL total nicotine concentration
Study: 37699050
Drug: E-liquids with
Normalized name: Aquasol E Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-liquids with 50 mg/mL total nicotine concentration
Study: 37699064
Drug: 120 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 μg RSVPreF3-AS01E (third dose)
Study: 37699064
Drug: Previous 2
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous 2 doses of RSVPreF3-AS01E
Study: 37699161
Drug: START (Startle
Approvals — FDA: no, EMA: no, PMDA: no
Description: START (Startle Adjuvant Rehabilitation Therapy) with 105-dB white noise GO cues during one third of trials
Study: 37699161
Drug: START (Startle
Approvals — FDA: no, EMA: no, PMDA: no
Description: START (Startle Adjuvant Rehabilitation Therapy)
Study: 37699162
Drug: Alpelisib (PIK3CA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib (PIK3CA inhibitor)
Study: 37699162
Drug: Poziotinib (EGFR/HER2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poziotinib (EGFR/HER2 inhibitor)
Study: 37699162
Drug: Nintedanib (FGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (FGFR inhibitor)
Study: 37699162
Drug: Abemaciclib (CDK4/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib (CDK4/6 inhibitor)
Study: 37699162
Drug: Durvalumab ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab ± Tremelimumab (anti-PD-L1/CTLA-4 inhibitor)
Study: 37699237
Drug: Managing chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Managing chemotherapy symptoms (e.g., medication, home remedies)
Study: 37699237
Drug: Anticipating and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticipating and mitigating symptoms (e.g., management of symptoms at home, anticipatory guidance)
Study: 37699237
Drug: Knowing when
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Knowing when to seek care (e.g., unexpected and unusual symptoms)
Study: 37699601
Drug: Scalp-sparing volumetric-modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp-sparing volumetric-modulated arc therapy (SSV)
Study: 37699634
Drug: Anti-PD-1 treatment
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 treatment (Tislelizumab) starting at Day 8 of radiation (concurrent plan)
Study: 37699634
Drug: Anti-PD-1 treatment
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 treatment (Tislelizumab) starting 2 weeks after completion of radiation (sequential plan)
Study: 37699634
Drug: Long-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course radiotherapy plus concurrent capecitabine (control arm)
Study: 37699634
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment (all arms)
Study: 37699709
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous KPL-404 dose 0.03, 0.3, 1, 3, or 10 mg/kg
Study: 37699709
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous KPL-404 dose 1 or 5 mg/kg
Study: 37700239
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 inhibitor
Study: 37700249
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous ascorbic acid (50 mg/kg every 6 h for 96 h)
Study: 37700288
Drug: EWS plus
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Dews Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EWS plus medication therapy management (EWS + MTM)
Study: 37700334
Drug: Daily smartphone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily smartphone-based monitoring and treatment including clinical feedback
Study: 37700334
Drug: Daily smartphone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily smartphone-based monitoring without clinical feedback
Study: 37700334
Drug: Daily smartphone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily smartphone-based mood monitoring only
Study: 37701986
Drug: Pembrolizumab-based combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab-based combination therapy
Study: 37702047
Drug: Dietary nitrate
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary nitrate supplementation (400 mg nitrate in 70 mL beetroot juice)
Study: 37702427
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (OA) combined with mechanical bowel preparation (MBP)
Study: 37702453
Drug: Topical pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pilocarpine HCl 1.25% (Pilo)
Study: 37702559
Drug: HCT 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCT 25 mg/day
Study: 37702588
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg i.v. on days 1, 8, 15, and 22 and bevacizumab 10 mg/kg i.v. on days 1 and 15 of a 4-week cycle
Study: 37702588
Drug: Temsirolimus and
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus and bevacizumab combination therapy
Study: 37702920
Drug: Sotrovimab 500
Normalized name: sotrovimab 500 MG in 8 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrovimab 500 mg (intravenous infusion on Day 1)
Study: 37703006
Drug: Evinacumab, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evinacumab, 15 mg/kg, intravenously Q4W
Study: 37703037
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy (DBT) for 1 year (36 sessions)
Study: 37703083
Drug: Elexacaftor/Tezacaftor/Ivacaftor treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elexacaftor/Tezacaftor/Ivacaftor treatment
Study: 37703248
Drug: Mindfulness-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based intervention (MBI) delivered by ecological momentary intervention (EMI) via a smartphone app, including daily practice prompts, mindfulness exercises, virtual counseling, and daily psychological status logs.
Study: 37703397
Drug: Open lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open lidocaine administration
Study: 37703397
Drug: Open capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open capsaicin administration
Study: 37703397
Drug: Hidden lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hidden lidocaine administration
Study: 37703397
Drug: Hidden capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hidden capsaicin administration
Study: 37703908
Drug: Ciclosporin (2-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin (2-3 mg/kg before transplantation and 3 mg/kg twice per day from postoperative day 1)
Study: 37703908
Drug: Tacrolimus (0.05-0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (0.05-0.1 mg/kg before transplantation and 0.1-0.2 mg/kg from postoperative day 1)
Study: 37704438
Drug: Unilateral anterior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral anterior quadratus lumborum block (30 mL of ropivacaine 0.375%)